Check-Cap Ltd (7CC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Check-Cap Ltd (7CC) has a cash flow conversion efficiency ratio of -0.149x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.54 Million ≈ $-4.14 Million USD) by net assets (€23.69 Million ≈ $27.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 7CC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Check-Cap Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Check-Cap Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Check-Cap Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Check-Cap Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Energy Development Company Limited
NSE:ENERGYDEV
|
-5.422x |
|
Ragnar Metals Ltd
AU:RAG
|
-0.028x |
|
COSCIENS Biopharma Inc.
NASDAQ:CSCI
|
-0.627x |
|
Green Earth Group N.V.
AS:HWK
|
0.038x |
|
Jupiter Neurosciences, Inc. Common Stock
NASDAQ:JUNS
|
1.293x |
|
Allmed Solutions Ltd
TA:ALMD
|
-0.241x |
|
Taranis Resources Inc
V:TRO
|
-0.019x |
|
SenesTech Inc
NASDAQ:SNES
|
-0.122x |
Annual Cash Flow Conversion Efficiency for Check-Cap Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Check-Cap Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 7CC stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.44 Million ≈ $4.02 Million |
€-46.00K ≈ $-53.78K |
-0.013x | -100.24% |
| 2024-12-31 | €-1.45 Million ≈ $-1.70 Million |
€-8.00 Million ≈ $-9.36 Million |
5.520x | +871.22% |
| 2023-12-31 | €23.69 Million ≈ $27.69 Million |
€-16.95 Million ≈ $-19.82 Million |
-0.716x | -58.06% |
| 2022-12-31 | €41.31 Million ≈ $48.30 Million |
€-18.71 Million ≈ $-21.87 Million |
-0.453x | -41.13% |
| 2021-12-31 | €50.69 Million ≈ $59.26 Million |
€-16.26 Million ≈ $-19.01 Million |
-0.321x | +59.93% |
| 2020-12-31 | €16.38 Million ≈ $19.15 Million |
€-13.11 Million ≈ $-15.33 Million |
-0.801x | +61.14% |
| 2019-12-31 | €6.23 Million ≈ $7.29 Million |
€-12.84 Million ≈ $-15.01 Million |
-2.060x | -165.41% |
| 2018-12-31 | €13.03 Million ≈ $15.23 Million |
€-10.11 Million ≈ $-11.82 Million |
-0.776x | +48.99% |
| 2017-12-31 | €5.91 Million ≈ $6.90 Million |
€-8.99 Million ≈ $-10.51 Million |
-1.522x | -99.89% |
| 2016-12-31 | €10.41 Million ≈ $12.17 Million |
€-7.92 Million ≈ $-9.26 Million |
-0.761x | -- |
About Check-Cap Ltd
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.